Dose modifications | KISQALI® (ribociclib) Professional Site

For Healthcare Professionals Outside the US
KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)—negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

The only CDK4/6 inhibitor that offers adjustable dosing without the need for a new prescription mid-cycle^1-3

Dose adjustments to reduce the number of tablets taken

Each film-coated tablet contains 200 mg of ribociclib¹
Dose adjustments for AEs should be made in a stepwise order by reducing the number of tablets taken¹
Dose modification of KISQALI is recommended based on individual safety and tolerability¹
If dose reduction below 200 mg/day is required, discontinue treatment¹

survival-benefit

aBC, advanced breast cancer; AE, adverse event; AI, aromatase inhibitor; CDK, cyclin-dependent kinase.

References: 1. KISQALI [Summary of Product Characteristics]. Novartis Pharma AG; 2019. 2. Ibrance [Summary of Product Characteristics]. Pfizer Inc: 2018. 3. Verzenios [Summary of Product Characteristics]. Eli Lilly and Company; 2018. 4. De Laurentiis M, Merino L, Hart L, et al. Impact of ribociclib (RIB) dose reduction on overall survival in patients with HR+/HER2– advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7 [abstract]. Presented at: ESMO Virtual Congress 2020; Sept. 14-Oct. 18, 2020.